Needham Maintains Buy on AtriCure, Raises Price Target to $70
Needham analyst Mike Matson maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $64 to $70.
Share
Why It Matters
A money expert raised their price target for AtriCure stock to $70. This means they still think it's a good company to own long term.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.